BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ferreira E, Oliveira N, Marques M, Francisco L, Santos A, Carreira A, Campos M. Eculizumab for the treatment of an atypical hemolytic uremic syndrome with mutations in complement factor I and C3. Nefrologia 2016;36:72-5. [PMID: 26541438 DOI: 10.1016/j.nefro.2015.07.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
Number Citing Articles
1 Pérez-Cruz FG, Villa-Díaz P, Pintado-Delgado MC, Fernández_Rodríguez ML, Blasco-Martínez A, Pérez-Fernández M. Hemolytic uremic syndrome in adults: A case report. World J Crit Care Med 2017; 6(2): 135-139 [PMID: 28529915 DOI: 10.5492/wjccm.v6.i2.135] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
2 Lumbreras J, Subias M, Espinosa N, Ferrer JM, Arjona E, Rodríguez de Córdoba S. The Relevance of the MCP Risk Polymorphism to the Outcome of aHUS Associated With C3 Mutations. A Case Report. Front Immunol 2020;11:1348. [PMID: 32765494 DOI: 10.3389/fimmu.2020.01348] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]